Compare SEGG & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEGG | RNAZ |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 8.5M |
| IPO Year | 2023 | 2021 |
| Metric | SEGG | RNAZ |
|---|---|---|
| Price | $1.36 | $8.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $280.00 |
| AVG Volume (30 Days) | N/A | ★ 8.4K |
| Earning Date | N/A | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $6.15 |
| 52 Week High | N/A | $468.44 |
| Indicator | SEGG | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 33.73 | 34.32 |
| Support Level | $1.23 | $8.20 |
| Resistance Level | $1.80 | $9.00 |
| Average True Range (ATR) | 0.27 | 0.40 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 40.79 | 0.00 |
Lottery.com Inc is a provider of domestic and international lottery products and services. As an independent third-party lottery game service, the Company offers a platform that it developed and operates to enable the remote purchase of legally sanctioned lottery games in the U.S. and abroad. The Company's revenue-generating activities are focused on (i) offering the Platform via the Lottery.com app and its websites to users located in the U.S. and international jurisdictions where the sale of lottery games is legal and its services are enabled for the remote purchase of legally sanctioned lottery games; (ii) offering an internally developed, created and operated business-to-business application programming interface of the Platform to enable commercial partners in permitted U.S.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.